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Abstract
Introduction The aim of the study was to evaluate the activity of
a combination of doxorubicin (Dox), paclitaxel (Pacl) and 5-
fluorouracil (5-FU), to define the most effective schedule, and to
investigate the mechanisms of action in human breast cancer
cells.
Methods The study was performed on MCF-7 and BRC-230
cell lines. The cytotoxic activity was evaluated by
sulphorhodamine B assay and the type of drug interaction was
assessed by the median effect principle. Cell cycle perturbation
and apoptosis were evaluated by flow cytometry, and apoptosis-
related marker (p53, bcl-2, bax, p21), caspase and thymidylate
synthase (TS) expression were assessed by western blot.
Results 5-FU, used as a single agent, exerted a low cytotoxic
activity in both cell lines. The Dox→Pacl sequence produced a
synergistic cytocidal effect and enhanced the efficacy of
subsequent exposure to 5-FU in both cell lines. Specifically, the
Dox→Pacl sequence blocked cells in the G2-M phase, and the
addition of 5-FU forced the cells to progress through the cell
cycle or killed them. Furthermore, Dox→Pacl pretreatment
produced a significant reduction in basal TS expression in both
cell lines, probably favoring the increase in 5-FU activity. The
sequence Dox→Pacl→48-h washout→5-FU produced a
synergistic and highly schedule-dependent interaction
(combination index < 1), resulting in an induction of apoptosis in
both experimental models regardless of hormonal, p53, bcl-2 or
bax status. Apoptosis in MCF-7 cells was induced through
caspase-9 activation and anti-apoptosis-inducing factor
hyperexpression. In the BRC-230 cell line, the apoptotic
process was triggered only by a caspase-dependent
mechanism. In particular, at the end of the three-drug treatment,
caspase-8 activation triggered downstream executioner
caspase-3 and, to a lesser degree, caspase-7.
Conclusion In our experimental models, characterized by
different biomolecular profiles representing the different biology
of human breast cancers, the schedule Dox→Pacl→48-h
washout→5-FU was highly active and schedule-dependent and
has recently been used to plan a phase I/II clinical protocol.
Introduction
Breast cancer is still a leading cause of cancer death in
women in the United States and Europe [1]. Adjuvant chemo-
therapy has been shown to provide disease-free and overall
survival benefits for patients with node-positive breast cancer
in large meta-analyses conducted by the Early Breast Cancer
Trialists' Collaborative Group [2]. A study by Weiss et al. [3],
however, showed that the overwhelming majority (80%) of
node-positive patients relapse and die within 26 years of diag-
nosis despite the use of cyclophasphamide-methotrexate-5-
fluorouracil (CMF)-based adjuvant chemotherapy. The devel-
opment of drugs and strategies to improve relapse-free and
overall survival therefore remains a high priority.R681
5FdUMP = 5-fluoro-deoxyuridine-monophosphate; 5-FU = 5-fluorouracil; 5FUTP = 5-fluoro-deoxyuridine-triphosphate; AIF = apoptosis-inducing fac-
tor; CI = combination index; CMF = cyclophasphamide-methotrexate-5-fluorouracil; DMEM = Dulbecco's modified Eagle's medium; DMSO = dimeth-
ylsulfoxide; Dox = doxorubicin; FCS = fetal calf serum; FEC = fluorouracil, epirubicin, cyclophosphamide; Pacl = paclitaxel; SRB = sulforhodamine 
B; TS = thymidylate synthase.
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drugs for the treatment of breast cancer and anthracycline-
containing regimens have an impact, albeit modest, on patient
survival [2,4].
Paclitaxel (Pacl), belonging to the chemical class of taxanes, is
capable of inducing in vitro apoptosis, independently of p53
status, through its microtubule-stabilizing activity and, as
recently published, by inducing the release of cathepsin B
from lysosomes [5]. From a clinical point of view, taxanes
appear to be promising, although their real impact on the nat-
ural history of breast cancer has yet to be defined. A similar
impact of Pacl on clinical response has been reported, how-
ever, for patients with wild-type or p53-mutated cancers [6-9],
the latter representing 15% of in situ breast carcinomas and
50% of invasive disease [10]. Moreover, the loss of normal
p53 function sensitizes in vitro cells to drug activity [11-13],
hence the interest to use the taxane combination with other
drugs as clinical therapy. The association of a taxane with an
anthracycline is based on evidence that the two drugs have
different mechanisms of action and toxicities and are not
cross-resistant. Moreover, in vitro studies [14-17] on human
cell lines and primary breast cancer cultures have shown a
schedule-dependent interaction of the two drugs. Phase I and
II studies with the doxorubicin (Dox)-Pacl sequence defined by
preclinical studies have reported objective responses ranging
from 40% to more than 90% [18,19], and a recent prospec-
tive phase III study on advanced breast cancer reported an
impressive response rate (up to 94%) for the sequence, which
was shown to prolong overall survival compared to the fluorou-
racil, epirubicin, cyclophosphamide (FEC) combination [20].
5-Fluorouracil (5-FU), one of the most important agents for the
treatment of colorectal, head and neck, pancreatic and breast
carcinomas, is a pro-drug that requires conversion to 5-fluoro-
deoxyuridine-monophosphate (5FdUMP) and 5-fluoro-deoxyu-
ridine-triphosphate (5FUTP) in cancer cells. Several in vitro
studies on human solid tumor cell lines have demonstrated the
positive and schedule-dependent interaction of Pacl and 5-FU
[21-23]. A synergistic effect was obtained only when tumor
cells were exposed to Pacl followed by antimetabolites. Con-
versely, simultaneous exposure to the two drugs or pretreat-
ment with 5-FU reduced overall cell killing compared to Pacl
alone. Specifically, it has been demonstrated that a short pre-
treatment with Dox increases the activity of Pacl and of the
Pacl→gemcitabine sequence [24]. In the light of these pre-
clinical and clinical observations, the present study aimed to
investigate the cytotoxic effect produced by the combination
of Dox, Pacl and 5-FU in human breast cancer cell lines and to




The study was performed on two human breast cancer cell
lines: a commercial line (MCF-7; 40-h doubling time, obtained
from the American Type Culture Collection (Rockville, MD),
and a cell line established in our laboratory (BRC-230; 30-h
doubling time) [25]. MCF-7 cells express estrogen receptors
and bcl-2, harbor a wild-type p53 gene and lack pro-caspase-
3. BRC-230 cells have no estrogen receptors, do not express
bcl-2, contain a p53 gene mutation, and express pro-caspase-
3. Culture medium was composed of DMEM/HAM F12 (1:1)
supplemented with FCS (10% v/v), glutamine (2 mM) (Mascia
Brunelli SpA, Milan, Italy) and insulin (10 µg/ml) (Sigma
Aldrich, Milan, Italy). Cells were used in the exponential growth
phase for all experiments.
In vitro chemosensitivity assay
The sulforhodamine B (SRB) assay was used according to the
method of Skehan et al. [26]. Briefly, 104 cells in 100 µl of
medium/well were plated in 96-well flat-bottomed microtiter
plates and 18 to 24 h after plating (an adequate time for expo-
nential growth recovery) culture medium was replaced with
fresh medium either containing or not containing the drugs. At
the end of drug exposure, cells were fixed for 1 h and stained
with 0.4% SRB (Sigma Aldrich) dissolved in 1% acetic acid
for 30 minutes. The plates were then washed four times with
1% acetic acid to remove unbound stain, air-dried and solubi-
lized in 100 µl of 10 mM unbuffered Tris base (tris(hydroxyme-
thyl)aminomethane) solution. The optical density of treated
cells was detected at 490 nm. Each sample was run in octu-
plet, and each experiment was repeated three times. There-
fore, each experimental value in the graphs represents the
median of 24 samples.
Drugs and chemicals
Dox (Pharmacia Italia SpA, Milan, Italy) and 5-FU (Roche,
Milan, Italy) were diluted in sterile saline solution, and Pacl
(Bristol Meyers Squibb, Rome, Italy) was diluted in 95% etha-
nol. The drugs were then divided into aliquots and stored at -
70°C. Drug stocks were freshly diluted in culture medium
before each experiment. Z-LEHD-FMK (caspase-9 inhibitor)
and Z-DEVD-FMK (caspase-3 inhibitor) (BD Biosciences
Pharmingen, Milan, Italy) were solubilized in dimethylsulfoxide
(DMSO) (Sigma Aldrich) and freshly diluted in culture medium
at a concentration of 100 µM before each experiment. The
final DMSO concentration never exceeded 1% and this condi-
tion was used as control in each experiment.
Drug exposure
The drugs were tested singly at scalar concentrations of
0.001, 0.01, 0.1 and 1 µg/ml for Pacl and Dox, and 0.01, 0.1,
1 and 10 µg/ml for 5-FU. The exposure time to each single
agent (4 h for Dox and 24 h for Pacl or 5-FU) was chosen from
the dose inhibition rate curves and represented the time that
produced the maximum effect. Control samples were
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evaluation of the cytotoxic effect was performed immediately
after the end of drug exposure. Each experiment testing the
activity of the drugs singly and in combination was run in octu-
plet and repeated three times.
Drug combinations
Dox/Pacl
Based on our previous results, in sequence experiments, cells
were exposed to Dox for 4 h, after which the drug-containing
medium was removed and cells were incubated for 24 h with
fresh medium containing Pacl. In all the combination experi-
ments, each drug was tested at the four different concentra-
tions used for single drug exposure (0.001, 0.01, 0.1 and 1
µg/ml) at a 1:1 ratio.
Dox/Pacl/5-FU
Dox and Pacl were used as described above. After exposure,
the medium was removed and cells were cultured in drug-free
medium for 48 h, after which they were treated with 5-FU for
24 h. This scheme, derived from previous experimental stud-
ies, was considered as the most effective. In these combina-
tion experiments, the three drugs were tested at the four
different concentrations used for single drug exposure (0.001,
0.01 and 0.1 and 1 µg/ml for Dox and Pacl and 0.01, 0.1, 1
and 10 µg/ml for 5-FU) at a 1:1:10 ratio.
The cytotoxic effect was evaluated immediately after the end
of the three-drug exposure. Controls were processed as
treated samples but in drug-free medium.
Table 1
Combination index values induced by sequential treatments
MCF-7 BRC-230
CI value at inhibition of CI value at inhibition of
Drug combination Combination ratio 75% 90% 95% 75% 90% 95%
Dox→Pacl 1:1 0.3 0.3 0.4 0.1 0.2 0.2
Dox→Pacl→48-h washout→5-FU 1:1:10 0.0005 0.002 0.005 0.002 0.007 0.02
5-FU, 5-fluorouracil; CI, combination index; Dox, doxorubicin; Pacl, paclitaxel.
Figure 1
Effect of different drug treatments on the survival of MCF-7 and BRC-230 breast cancer cell lines. (a) 5-FU, (b) Dox→Pacl sequence and (c) 
Dox→Pacl→5-FU treatment. D1, D2, D3 and D4 represent the doses of the three drugs used in the sequence (see Materials and methods). Each 
data point is the average of at least three independent experiments performed in octuplet. The standard deviation never exceeded 5%.
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The type of drug interaction was determined by the median
effect principle according to the method of Chou and Talalay
[27] and was applied for the three-drug treatment [28]. On the
basis of this approach, the interaction between the three drugs
was quantified by determining a combination index (CI) at
increasing levels of cell kill. CI values lower than, equal to, or
higher than 1 indicated synergy, additivity, or antagonism,
respectively.
Cell cycle perturbations
Cells (2 × 105) were cultured in medium either containing or
not containing (control) the cytotoxic drugs in sequence at a
concentration of 0.1 µg/ml for Dox and Pacl and 1 µg/ml for 5-
FU. After drug exposure, cells were harvested and stained in a
solution containing RNAase (10 Ku/ml; Sigma-Aldrich), Noni-
det P40 (0.01%; Sigma-Aldrich) and propidium iodide (1 µg/
ml; Sigma-Aldrich). Samples were analyzed 30 to 60 minutes
later by flow cytometry (Becton Dickinson Italia SpA, Milan,
Italy). Data acquisition (10,000 events for each sample) was
performed using CELLQuest software (Becton Dickinson Ita-
lia). Data were elaborated using Modfit (DNA Modelling Sys-
tem) software (Verity Software House Inc., Topsham, ME,
USA) and expressed as fractions of cells in the different cell
cycle phases. Samples were run in triplicate and each experi-
ment was repeated three times.
Apoptosis
Apoptosis was evaluated by flow cytometric analysis accord-
ing to the previously described TUNEL assay procedure [29].
Briefly, the cells, treated as outlined above, were trypsinized,
fixed, exposed to TUNEL reaction mixture and counterstained
with propidium iodide before FACS analysis.
Trypsinized cells were treated with anti-Fas antibody (DakoCy-
tomation Denmark A/S, Glostrup, Denmark) diluted 1:500 for
1 h at 4°C to evaluate Fas receptor expression by flow cytom-
etry. Cells were then incubated with a goat-mouse FITC-con-
jugated secondary antibody (DakoCytomation). Flow
cytometric data acquisition and analysis were performed using
CELLQuest software (Becton Dickinson Italia). For each sam-
ple, 15,000 events were recorded.
Western blot analysis
After the three-drug exposure, cells were treated according to
the previously described western blot procedure [29]. The
monoclonal antibodies used were anti-p53 (PAb 1801, Biopt-
ica, Milan, Italy) 1:400, anti-bcl-2 (clone 124, Dako Corpora-
tion, Santa Barbara, CA, USA) 1:50, anti-p21 (clone DCS-
60.2, Bioptica) 1:100, antithymidylate synthase (clone TS
106, Bioptica) 1:100 and anti-caspase-8 (clone 12F5, Alexis
Biochemicals Corporation, Lausanne, Switzerland) 1:500. We
used polyclonal antibodies for anti-caspases -3, -6, -7 and -9
(Cell Signaling Technology, Inc., Beverly, MA, USA), all diluted
at 1:500, anti-apoptosis-inducing factor (AIF) (Chemicon
International, Inc., Temecula, CA, USA) 1:500 and anti-bax
(Pharmingen, San Diego, CA, USA) 1:1000. Actin polyclonal
antibody (Sigma-Aldrich) was used as control to demonstrate
equal loading. The samples were analyzed using QuantiScan
software (Biosoft, Cambridge, UK).
Results
Cytotoxic activity
The cytotoxic activity of 5-FU, of the 4-h Dox→24-h Pacl
sequence, and of the 4-h Dox→24-h Pacl→48-h wash-
out→24-h 5-FU exposure is reported in Fig. 1. 5-FU showed a
moderate cytotoxic activity in both cell lines. The Dox→Pacl
sequence produced a strong cytocidal effect and an important
synergism in MCF-7 and BRC-230 cell lines, as shown by
Chou-Talalay analysis (Table 1). The synergistic effect dramat-
ically increased, starting from the lowest doses, when cells
were treated with 5-FU after the sequence
anthracycline→taxane→48-h washout (Fig. 1).
Figure 2
BRC-230 cells after Dox (0.1 µg/ml)→Pacl (0.1 µg/ml)→48-h washout→5-FU (1 µg/ml) treatment
washout→5-FU (1 µg/ml) treatment. Apoptotic nuclei stained with 
DAPI show intense fluorescence corresponding to chromatin conden-
sation (arrow heads) and fragmentation (arrows).
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Distribution of cells in the different cell cycle phases (%) and apoptotic cells (%) after different treatments
MCF-7 BRC-230
Treatment G1 S G2-M Apoptosis G1 S G2-M Apoptosis
Untreated cells 48 40 12 1 55 33 12 2
Dox→Pacl 6a 14a 80a 22a 10a 27a 63a 15a
Dox→Pacl→48-h washout 3a 16a 81a 17a 5a 11a 84a 15a
Dox→Pacl→48-h washout→5-FU 15a 49 36a 40a 20a 42a 38a 37a
aP < 0.05 by t-test. 5-FU, 5-fluorouracil; Dox, doxorubicin; Pacl, paclitaxel.
Figure 3
Inhibition of apoptosis. Results from TUNEL assay showing inhibition induced by Dox (0.1 µg/ml)→Pacl (0.1 µg/ml)→48-h washout→5-FU (1 µg/
ml) treatment in (a) BRC-230 cells in the presence of caspase-3 (casp-3) inhibitor and (b) MCF-7cells in the presence of caspase-9 (casp-9) 
inhibitor.
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A 4-h treatment with Dox or a 24-h exposure to 5-FU did not
induce biologically relevant cell cycle perturbations (full recov-
ery was observed after a 24-h culture in drug-free medium) or
significant apoptosis (data not shown). Conversely, a 24-h
treatment with Pacl produced a considerable increase of cells
in G2-M phases, with a decrease in G1 phase, which further
increased 24 h after drug removal and began to recover after
48 h. Moreover, about 10% and 15% of apoptotic cells were
detected in BRC 230 and MCF-7 cell lines, respectively (data
not shown). The Dox→Pacl sequence caused a dramatic
block of cells in G2-M and a decrease in G1-S phases, which
persisted up to 48 h after drug removal. In parallel, the fraction
of apoptotic cells (Fig. 2) rose from 15% to 22% as washout
time increased. This finding was similar in both cell lines (Table
2).
Cell cycle perturbations consisting of higher and lower frac-
tions of cells in G2 and G1/S phases, respectively, persisted
after exposure to the Dox→Pacl→5-FU sequence (Table 2),
albeit to a lesser extent than that observed after the Dox→Pacl
sequence. A statistically significant increase of up to 40% was
observed in apoptotic cells.
The presence of caspase-9 inhibitor during exposure to the
Dox→Pacl→5-FU sequence induced a reduction from 40% to
21% in the apoptotic cell fraction in the MCF-7 line (Fig. 3a).
Similarly, the presence of caspase-3 inhibitor during the three-
drug treatment caused a reduction in the apoptotic fraction
from 37% to about 6% in BRC-230 cells (Fig. 3b).
Apoptotic-related markers
In MCF-7 cells basally expressing bcl-2 and harboring wild-
type p53, Dox or 5-FU did not have any effect on apoptotic-
related markers, whereas Pacl caused bcl-2 phosphorylation
as well as p53 overexpression (data not shown). Bcl-2 phos-
phorylation further increased after the Dox→Pacl sequence.
An increase in pro-apoptotic bax, p21 and p53 expression
was observed at the end of the two-drug sequence and was
even more evident after the three-drug treatment (Fig. 4).
The BRC-230 cell line, lacking bcl-2 and with mutated p53,
showed no induction of bax or p53 overexpression after any
treatment. Conversely, Dox→Pacl treatment induced an
increase in p21 expression that persisted 48 h after drug
removal and was still evident at the end of the three-drug expo-
sure (Fig. 4).
With regard to the caspase cascade, caspase-9 was activated
in the MCF-7 cell line after the Dox→Pacl sequence and fur-
ther increased at the end of the three-drug treatment. Similar
behavior was observed for caspase-8, but its active 18 kDa
fragment was not detected. Caspase-7 activation was
induced after the three-drug sequence only (Fig. 5), whereas
Figure 4
Protein levels of bcl-2, bax, p53 and p21 following different drug exposur s expo-
sures. Protein (50 µg) was loaded for the controls and treated samples: 
(a) untreated cells; (b) Dox (0.1 µg/ml)→Pacl (0.1 µg/ml); (c) Dox (0.1 
µg/ml)→Pacl (0.1 µg/ml)→48-h washout; (d) Dox (0.1 µg/ml)→Pacl 
(0.1 µg/ml)→48-h washout→5-FU (1 µg/ml).
Figure 5
Western blot analysis of caspases and apoptosis-inducing factor (AIF) proteins fo lowi g different tre tments
proteins following different treatments. Protein (50 µg) was loaded for 
the controls and treated samples: (a) untreated cells; (b) Dox (0.1 µg/
ml)→Pacl (0.1 µg/ml); (c) Dox (0.1 µg/ml)→Pacl (0.1 µg/ml)→48-h 
washout; (d) Dox (0.1 µg/ml)→Pacl (0.1 µg/ml)→48-h washout→5-FU 
(1 µg/ml).
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of the treatments. In parallel, a hyperexpression of AIF was
observed at the end of both two- and three-drug treatments
(Fig. 5).
In BRC-230 cells, an induction of caspase-8, with its 18 kDa
fragment, was observed at the end of the Dox→Pacl exposure
and was still present after the three-drug treatment. Caspases
-3 and -7 were activated 48 h after the end of Dox→Pacl treat-
ment and persisted after the three-drug treatment. Conversely,
none of the treatments induced caspase-9 (Fig. 5) or -6
expression (data not shown) or altered Fas expression (data
not shown).
Thymidylate synthase
Thymidylate synthase (TS) was basally expressed in both cell
lines, but at higher levels in MCF-7 than in BRC-230, as seen
by a clear western blotting band at 36 kDa (Fig. 6). 5-FU expo-
sure induced a more evident increase in TS expression in the
BRC-230 than in the MCF-7 cell line, as demonstrated by the
appearance of an additional band of approximately 38 kDa.
Dox-Pacl treatment induced a significant decrease in TS
expression in MCF-7 cells characterized by higher basal TS
levels, and a slight reduction in low basal TS levels in the BRC-
230 cell line. Exposure to 5-FU after Dox→Pacl treatment
induced an increase in TS protein expression that was, how-
ever, lower than that induced by treatment with 5-FU alone, in
both cell lines. Moreover, in BRC-230 cells, the three-drug
treatment did not induce a detectable TS ternary complex (Fig.
6).
Discussion
To date the clinical design of polychemotherapeutic protocols
has mainly taken into account information derived from exper-
imental studies on mechanisms of action of different agents
and has favored combinations of drugs with complementary
toxicities, but it has been clearly demonstrated that sequenc-
ing and timing of administration are important to optimize drug
activity.
Our results confirmed the synergistic interaction of the
Dox→Pacl treatment [14-16] and showed that this sequence
enhances the efficacy of subsequent exposure to 5-FU, as
observed in our previous studies using the antimetabolite
gemcitabine [18,24]. In particular, we observed that cells, as
expected, were trapped in the G2-M phase after the
Dox→Pacl sequence, and the subsequent addition of 5-FU
forced cells to progress through the cell cycle or killed them.
In fact, the three-drug treatment doubled the percentage of
apoptotic cells produced by the Dox→Pacl sequence in both
experimental cell lines.
In MCF-7 cells, phosphorylation of the anti-apoptotic gene and
persistent upregulation of pro-apoptotic markers was induced
by the Dox→Pacl sequence and further enhanced by exposure
to 5-FU. It can be hypothesized that the ensuing mitochondrial
instability led to apoptosis through both the cytochrome-c-
mediated activation of caspases -9 and -7 and the release of
AIF. The important role played by AIF in the apoptosis process
in MCF-7, which is lacking in caspase-3 [30], was demon-
strated by the partial cell death inhibition observed in the pres-
ence of caspase-9 inhibitor during the three-drug treatment.
In the BRC-230 cell line, apoptosis was triggered by the acti-
vation of caspases -8 and -3 and, albeit to a lesser degree,
caspase-7. In particular, the pivotal role of caspase-3 was
highlighted by the almost complete suppression of apoptosis
in the presence of caspase-3 inhibitor during the three-drug
exposure.
TS protein was also modulated after the different treatments in
both cell lines. TS, which converts dUMP to dTMP, is the pri-
mary target of fluoropyrimidine activity [31]. It represents the
rate-limiting nucleotide in DNA synthesis and its overexpres-
sion has been shown to be associated with resistance to 5-
FU-based treatments. Our results showed, as already reported
in colon cancer cell lines [32], an increase in TS free protein
and the formation of TS ternary complex following 5-FU expo-
sure. This increase was more evident in the p53-mutated
BRC-230 line than in wild-type p53 MCF-7 cells. Following
the Dox→Pacl treatment, basal TS expression was signifi-
Figure 6
Western blot analysis of thymidylate synthase and ternary complex. (a) Untreated cells; (b) 5-FU (1 µg/ml); (c) Dox (0.1 µg/ml)→Pacl (0.1 µg/ml); 
(d) Dox (0.1 µg/ml)→Pacl (0.1 µg/ml)→48-h washout→5-FU (1 µg/ml). 50 µg of protein were loaded for the controls and treated samples.
Breast Cancer Research    Vol 7 No 5    Zoli et al.
R688cantly reduced in MCF-7 and also, albeit to a lesser degree, in
BRC-230 cells. Subsequent exposure to 5-FU increased free
TS expression without, however, reaching the levels observed
after treatment with 5-FU alone. In particular, the increase
involved only free TS in BRC-230 and was associated with the
formation of the ternary complex, albeit fourfold lower than that
induced by 5-FU alone, in MCF-7 cells.
In conclusion, apoptosis was observed after the Dox→Pacl
sequence and was even more evident when followed by 5-FU,
which induced an important apoptosis in cell lines character-
ized by different estrogen receptor status and apoptosis-
related markers, both representative of the heterogeneous
biology of clinical breast cancers. The efficacy of the antime-
tabolite was favored by an increase in TS levels following
exposure to anthracycline and taxane.
Conclusion
The present preclinical study permitted us to define the most
effective three-drug sequence, providing the basis for the
rationale of an ongoing phase I/II breast cancer clinical proto-
col in which the oral formulations of Dox and 5-FU are used to
reduce toxicity and increase safety of treatment schemes.
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